The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Boston Scientific's revenues will wane -4.2% and EPS will contract 0.0%.
The average estimate for revenue is $1.79 billion. On the bottom line, the average EPS estimate is $0.09.
Last quarter, Boston Scientific booked revenue of $1.82 billion. GAAP reported sales were 1.5% lower than the prior-year quarter's $1.85 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.11. GAAP EPS of $0.04 for Q4 were 43% lower than the prior-year quarter's $0.07 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 66.6%, 90 basis points better than the prior-year quarter. Operating margin was 13.2%, 120 basis points worse than the prior-year quarter. Net margin was 3.3%, 250 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $7.19 billion. The average EPS estimate is $0.42.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 748 members out of 937 rating the stock outperform, and 189 members rating it underperform. Among 176 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 156 give Boston Scientific a green thumbs-up, and 20 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Boston Scientific is hold, with an average price target of $6.38.
Is Boston Scientific the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Boston Scientific to My Watchlist.